keyword
MENU ▼
Read by QxMD icon Read
search

phase III carcinoma

keyword
https://www.readbyqxmd.com/read/29145036/liver-immunotolerance-and-hepatocellular-carcinoma-patho-physiological-mechanisms-and-therapeutic-perspectives
#1
REVIEW
Gaël S Roth, Thomas Decaens
At the moment of the diagnosis of hepatocellular carcinoma (HCC), 70% of patients have only access to palliative treatments, with very few therapeutic options. Liver immunology is very specific, and liver immunotolerance is particularly developed because of the constant and massive influx of antigens. Deregulation of hepatic immunotolerance is implicated in chronic liver diseases development and particularly in liver carcinogenesis. For these reasons, HCC may be an excellent candidate for anticancer immunotherapies such as immune checkpoint inhibitors targeting CTLA-4 and PD-L1/PD-1...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29142833/the-effect-of-long-term-thyroid-stimulating-hormone-suppressive-therapy-on-the-gonadal-steroid-hormones-of-patients-with-thyroid-carcinoma-after-surgery
#2
Xiaoli Liu, Ying Zhou, Nan Liang, Yang Hong, Gianlorenzo Dionigi, Hui Sun
Background: To analyze the effect of long-term thyroid-stimulating hormone (TSH) suppressive therapy on the gonadal hormones and related symptoms in patients after surgery. Methods: From 2008 to 2011, totally 238 patients were recruited, who underwent thyroid surgery and subsequent TSH suppression treatment in Department of thyroid Surgery, China-Japan Union hospital, Jilin University. Then their postoperative follow-up data (3-8 years) were collected, including operational method, pathological diagnosis, whether processed radioiodine therapy and the period/dose of TSH suppression treatment...
October 2017: Gland Surgery
https://www.readbyqxmd.com/read/29136187/a-phase-iii-trial-of-a-single-early-intravesical-instillation-of-pirarubicin-to-prevent-bladder-recurrence-after-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma-jcog1403-utuc-thp-phase-iii
#3
Kenichi Miyamoto, Akihiro Ito, Masashi Wakabayashi, Junko Eba, Yoichi Arai, Hiroyuki Nishiyama, Mikio Sugimoto, Ryo Yamashita, Yoshiyuki Kakehi
Observation is the current standard for managing cases of Stage 0a-III upper tract urothelial carcinoma after radical nephroureterectomy. A randomized Phase III trial commenced in Japan during October 2016. The trial is designed to investigate the superiority of a single early intravesical instillation of pirarubicin, compared with observation, in terms of relapse-free survival after radical nephroureterectomy for Stage 0a-III upper tract urothelial carcinoma. During a 5-year period, 310 patients will be recruited from 43 Japanese institutions...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29132393/interferon-%C3%AE-inducible-protein-16-ifi16-is-required-for-the-maintenance-of-epstein-barr-virus-latency
#4
Gina Pisano, Arunava Roy, Mairaj Ahmed Ansari, Binod Kumar, Leela Chikoti, Bala Chandran
BACKGROUND: Epstein-Barr virus (EBV) exhibits both lytic and latent (Lat. I, II, and III) phases in an infected individual. It's during the latent phase of EBV that all EBV-associated cancers, including Burkitt's lymphoma, nasopharyngeal carcinoma and lymphoproliferative disease arise. Interferon-γ-inducible protein 16 (IFI16) is a well-established innate immune sensor and viral transcriptional regulator involved in response to invading DNA viruses. During latency, IFI16 remains in the nucleus, in part bound to the EBV genome; however, neither its role in EBV lytic cycle or latency has been established...
November 13, 2017: Virology Journal
https://www.readbyqxmd.com/read/29127587/copanlisib-first-global-approval
#5
Anthony Markham
Bayer are developing copanlisib (Aliqopa™)-a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor-as a treatment for various haematological and solid malignancies. The US FDA has granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies based on the results of a phase II trial. Phase III trials are underway evaluating copanlisib as treatment for relapsed/refractory diffuse large B-cell lymphoma and in combination with rituximab or rituximab-based chemotherapy or standard immunochemotherapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma...
November 10, 2017: Drugs
https://www.readbyqxmd.com/read/29122495/up-regulation-of-serum-periostin-and-squamous-cell-carcinoma-antigen-levels-in-infants-with-acute-bronchitis-due-to-respiratory-syncytial-virus
#6
Hiroaki Nakamura, Kenichi Akashi, Masako Watanabe, Shoichiro Ohta, Junya Ono, Yoshinori Azuma, Noriko Ogasawara, Keisuke Yamamoto, Norikazu Shimizu, Hiroyuki Tsutsumi, Kenji Izuhara, Toshio Katsunuma
BACKGROUND: Periostin and squamous cell carcinoma antigen (SCCA) are involved in the pathogenesis of asthma. Acute bronchitis due to respiratory syncytial virus (RSV) infection during infancy exhibits an asthma-like pathogenesis, suggesting that it may be associated with the subsequent development of asthma. However, the mechanism by which RSV infection leads to development of asthma has not yet been fully elucidated. METHODS: Infants younger than 36 months were enrolled and classified into three groups...
November 6, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29120911/immunotherapy-for-kidney-cancer-status-quo-and-the-future
#7
Jens Bedke, Viktoria Stühler, Arnulf Stenzl, Bernhard Brehmer
PURPOSE OF REVIEW: The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI). The review focus on the recent immunooncology developments and available trial results within the last 12 months. RECENT FINDINGS: ICI as monotherapy (nivolumab) or immunooncology and immunooncology combinations (nivolumab and ipilimumab) demonstrated positive results on prolonged overall survival in phase III trials...
November 7, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29089775/practical-management-of-adverse-events-associated-with-cabozantinib-treatment-in-patients-with-renal-cell-carcinoma
#8
REVIEW
Benjamin S Gerendash, Patricia A Creel
Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET, and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renal-cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC, cabozantinib was associated with a significant improvement in overall survival, progression-free survival, and antitumor response compared with everolimus. Adverse events (AEs) were common for patients receiving cabozantinib, but were effectively managed with supportive care and dose modifications, as discontinuations of cabozantinib due to an AE were infrequent...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29081658/understanding-the-positive-benefit-risk-profile-of-alemtuzumab-in-relapsing-multiple-sclerosis-perspectives-from-the-alemtuzumab-clinical-development-program
#9
REVIEW
Eva Havrdova, Jeffrey A Cohen, Dana Horakova, Ivana Kovarova, Eva Meluzinova
The introduction of high-efficacy therapies for relapsing-remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous interferon beta-1a demonstrated significantly reduced annualized relapse rates and improved magnetic resonance imaging outcomes, and were significantly more likely to achieve no evidence of disease activity and reduction in brain volume loss...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29079131/update-of-systemic-immunotherapy-for-advanced-urothelial-carcinoma
#10
REVIEW
Benjamin A Gartrell, Tianfang He, Janaki Sharma, Guru Sonpavde
PURPOSE: Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the perioperative settings for muscle-invasive disease and for metastatic disease. A large proportion of patients is cisplatin-ineligible and limited to less effective chemotherapeutic options. However, treatment options have recently expanded with the development of systemic immunotherapy with checkpoint inhibitors (CPIs)...
October 24, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29078210/-personalized-treatment-for-colorectal-carcinomas
#11
Sebastian Stintzing
Colorectal carcinoma (CRC) is a major cause for cancer related death in Western countries. Particularly in the metastatic stage (mCRC) 5-year survival rate remains low at around 15 %. Treatment decisions are influenced by tumor stage, location of the primary, and extend of metastases. The multidisciplinary tumor board with an experienced hepato-biliary surgeon, an interventional radiologist, the medical oncologist, the molecular pathologist and the radiation oncologist will gain further importance in the quest for the optimal treatment for each patient...
November 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29077166/correlation-between-rar-%C3%AE-expression-in-lung-squamous-cell-carcinoma-tissues-and-prognosis
#12
P-Z Hou, G Jian, Z-Q Ma, Y Xu
OBJECTIVE: To explore the retinoic acid receptor-β (RAR-β) expression in lung squamous cell carcinoma (LSCC) tissues and its prognosis. PATIENTS AND METHODS: SP assay was used to detect the RAR-β expression in 100 cases of surgically resected LSCC tissues and 20 cases of peritumoral normal lung tissues, and prognosis follow-up was conducted. RESULTS: The overall positive expression rate of RAR-β was 54.00%, which was not correlated with age, gender, phase and pathological type (p>0...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29063069/targeting-met-in-cancer-therapy
#13
REVIEW
Hong-Nan Mo, Peng Liu
MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in the origin of cancer. Several monoclonal antibodies and small-molecule inhibitors of c-MET have been evaluated in clinical trials. In patients with advanced non-small cell lung cancer, cabozantinib and crizotinib showed clear efficacy with a generally tolerable adverse events profile...
September 2017: Chronic Dis Transl Med
https://www.readbyqxmd.com/read/29059635/phase-ii-randomised-discontinuation-trial-of-cabozantinib-in-patients-with-advanced-solid-tumours
#14
Patrick Schöffski, Michael Gordon, David C Smith, Razelle Kurzrock, Adil Daud, Nicholas J Vogelzang, Yihua Lee, Christian Scheffold, Geoffrey I Shapiro
BACKGROUND: Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types. PATIENTS AND METHODS: Cabozantinib was administered (100 mg, once daily) to patients with advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo...
October 20, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29048330/calibration-and-analysis-of-a-multimodal-micro-ct-and-structured-light-imaging-system-for-the-evaluation-of-excised-breast-tissue
#15
David Martin McClatchy Iii, Elizabeth J Rizzo, Jeff Meganck, Josh Kempner, Jared Vicory, Wendy A Wells, Keith D Paulsen, Brian W Pogue
A multimodal micro-computed tomography (CT) and multi-spectral structured light imaging (SLI) system is introduced and systematically analyzed to test its feasibility to aid in margin delineation during breast conserving surgery (BCS). Phantom analysis of the micro-CT yielded a signal-to-noise ratio (SNR) of 34, a contrast of 1.64, and a minimum detectable resolution of 240 m for a 1.2 min scan. The SLI system, spanning wavelengths 490 nm to 800 nm and spatial frequencies up to 1.37 mm-1, was evaluated with aqueous tissue simulating phantoms having variations in particle size distribution, scatter density, and blood volume fraction...
October 19, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29044458/patient-reported-quality-of-life-outcomes-after-de-escalated-chemoradiation-for-human-papillomavirus-positive-oropharyngeal-carcinoma-findings-from-a-phase-2-trial
#16
John V Hegde, Narek Shaverdian, Megan E Daly, Carol Felix, Deborah L Wong, Michael H Rosove, Jordan H Garst, Pin-Chieh Wang, Darlene Veruttipong, Shyam Rao, Ruben C Fragoso, Jonathan W Riess, Michael L Steinberg, Allen M Chen
BACKGROUND: The current study represents a subset analysis of quality-of-life (QOL) outcomes among patients treated on a phase 2 trial of de-escalated chemoradiation for human papillomavirus (HPV)-associated oropharyngeal cancer. METHODS: Eligibility included newly diagnosed, (American Joint Committee on Cancer, 7th edition) stage III or IV oropharyngeal squamous cell carcinoma, p16 positivity, age ≥ 18 years, and a Zubrod performance status of 0 to 1. Treatment was induction paclitaxel at a dose of 175 mg/m(2) and carboplatin at an area under the curve of 6 for 2 cycles followed by response-adapted, dose-reduced radiation of 54 Gy or 60 Gy with weekly concurrent paclitaxel at a dose of 30 mg/m(2) ...
October 17, 2017: Cancer
https://www.readbyqxmd.com/read/29040974/an-intergroup-randomized-phase-ii-study-of-bevacizumab-or-cetuximab-in-combination-with-gemcitabine-and-in-combination-with-chemoradiation-in-patients-with-resected-pancreatic-carcinoma-a-trial-of-the-ecog-acrin-cancer-research-group-e2204
#17
Jordan D Berlin, Yang Feng, Paul Catalano, James L Abbruzzese, Philip A Philip, Robert R McWilliams, Andrew M Lowy, Al B Benson Iii, A William Blackstock
OBJECTIVES: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS: Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab...
October 18, 2017: Oncology
https://www.readbyqxmd.com/read/29033542/axitinib-in-the-treatment-of-renal-cell-carcinoma-design-development-and-place-in-therapy
#18
REVIEW
Audrey Bellesoeur, Edith Carton, Jerome Alexandre, Francois Goldwasser, Olivier Huillard
Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors (VEGFRs). Axitinib is an oral second-generation TKI and a potent VEGFR inhibitor with a half maximal inhibitory concentration for the VEGF family receptors 10-fold lower than other TKIs. Axitinib activity in renal cell carcinoma (RCC) patients has been studied in various settings and particularly as second-line treatment. In this setting, axitinib with clinically based dose escalation compared to sorafenib has demonstrated an improvement in progression-free survival in a randomized Phase III trial leading to US Food and Drug Administration approval...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29031556/corrigendum-to-long-term-results-of-a-phase-ii-study-of-gemcitabine-and-cisplatin-chemotherapy-combined-with-intensity-modulated-radiotherapy-in-locoregionally-advanced-nasopharyngeal-carcinoma-oral-oncol-73-2017-118-123
#19
Mingyao Wu, Dan Ou, Xiayun He, Chaosu Hu
OBJECTIVES: To evaluate long-term results of a phase II study of induction and adjuvant gemcitabine and cisplatin (GP) chemotherapy with intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: One hundred and twelve patients (Stage III: 65, IVA-B: 47) with locoregionally advanced NPC were enrolled in this study. All patients received induction chemotherapy consisting of 1000 mg/m(2) gemcitabine on day 1 and 8, and cisplatin 25 mg/m(2) on day 1-3, every 3 weeks for 2 cycles...
October 11, 2017: Oral Oncology
https://www.readbyqxmd.com/read/29018997/gastrointestinal-perforation-related-to-lenvatinib-an-anti-angiogenic-inhibitor-that-targets-multiple-receptor-tyrosine-kinases-in-a-patient-with-metastatic-thyroid-cancer
#20
Emi Date, Kunio Okamoto, Souichi Fumita, Hiroyasu Kaneda
Lenvatinib, a novel potent multikinase inhibitor, was approved for the treatment of radioiodine-refractory differentiated thyroid cancer based on results from phase III trial (SELECT study). Thyroid cancer is a diverse disease that includes anaplastic thyroid cancer (ATC), which the most aggressive form of the disease, although it accounts for <2% of all thyroid cancers. Current treatments for ATC have limited efficacy. We report the case of a woman with recurrent well-differentiated papillary carcinoma of the thyroid that had transformed into ATC who developed a perforation of the small intestine secondary to a marked effect of lenvatinib...
October 11, 2017: Investigational New Drugs
keyword
keyword
86070
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"